---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-031920"
form_type: "8-K"
ticker: "ERNA"
cik: "0000748592"
company_name: "Ernexa Therapeutics Inc."
filed_at: "2026-07-02T20:30:32+00:00"
generated_at: "2026-07-02T20:32:06.559281+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Ernexa Therapeutics shareholders elect directors, ratify auditor, approve 2026 equity plan

## Summary
- All five director nominees elected: Bristol, Cicala, Luther, Ratner, Wexler; broker non-votes 161,165.
- Ratification of Haskell & White LLP as auditor for FY 2026: 590,236 for, 29,010 against, 495 abstentions.
- Approval of 2026 Omnibus Equity Incentive Plan: 363,640 for, 94,840 against, 96 abstentions, 161,165 broker non-votes.
- Quorum of 53.13% (619,741 of 1,166,333 shares) represented at the July 1, 2026 annual meeting.

## SEC filing metadata
- accession: 0001493152-26-031920
- form_type: 8-K
- ticker: ERNA
- cik: 0000748592
- company_name: Ernexa Therapeutics Inc.
- filed_at: 2026-07-02T20:30:32+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/748592/000149315226031920/0001493152-26-031920-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/748592/000149315226031920/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-031920
- JSON: https://secwatch.observer/filing/0001493152-26-031920.json
- Plain text: https://secwatch.observer/filing/0001493152-26-031920.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.